SCHEMBL9326293

SCHEMBL9326293

CCCNC(=O)c1cncs1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.46
POLB P06746 3/20 0.41
ACACB O00763 2/20 0.41
SMN1; SMN2 Q16637 3/20 0.41
GAA P10253 2/20 0.41
HPGD P15428 2/20 0.41
KDM4E B2RXH2 1/20 0.41
NPC1 O15118 1/20 0.41
ESR1 P03372 1/20 0.41
JMJD7 P0C870 1/20 0.41
MAPT P10636 1/20 0.41
STAT3 P40763 1/20 0.41
STAT1 P42224 1/20 0.41
RAB9A P51151 1/20 0.41
HRH3 Q9Y5N1 1/20 0.40
KIF11 P52732 1/20 0.40
ALDH1A1 P00352 2/20 0.39
CYP1A2 P05177 1/20 0.39
CYP2C19 P33261 1/20 0.39
ABL1 P00519 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3456432 0.86 KMT2A (0.49) KMT2AACACBSMN1; SMN2GAAHRH3
SCHEMBL9331210 0.84 KMT2A (0.47) KMT2APOLBACACBHPGDKDM4E
SCHEMBL15296855 0.80 KMT2A (0.44) KMT2AACACBKDM4EHRH3KIF11
SCHEMBL5196227 0.78 KMT2A (0.48) KMT2AACACBSMN1; SMN2GAANPC1
SCHEMBL28202712 0.78 KMT2A (0.45) KMT2AACACBSMN1; SMN2GAAHPGD
SCHEMBL22170857 0.78 KMT2A (0.42) KMT2AGAAKDM4EESR1
SCHEMBL3455204 0.76 RAB9A (0.62) KMT2ASMN1; SMN2NPC1RAB9ACYP1A2
SCHEMBL9329242 0.76 KMT2A (0.41) KMT2AACACBSMN1; SMN2GAAHPGD
SCHEMBL15625520 0.76 MCL1 (0.45) KMT2AACACBHRH3KIF11ABL1
SCHEMBL343489 0.76

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250084074-A1 SUBSTITUTED HETEROCYCLES AS HSET INHIBITORS MERCK PATENT GMBH (DE) 2025-03-13 US claimed
US-20180148440-A1 SUBSTITUTED 2-(CHROMAN-6-YLOXYL)-THIAZOLES AND THEIR USE AS PHARMACEUTICALS SANOFI SA (FR) 2018-05-31 US disclosed
US-20170037042-A1 SUBSTITUTED 2-(CHROMAN-6-YLOXYL)-THIAZOLES AND THEIR USE AS PHARMACEUTICALS SANOFI SA (FR) 2017-02-09 US disclosed
EP-2925316-A1 SUBSTITUTED AMINO-ARYLCARBOXAMIDES AS KCNQ2/3 MODULATORS Grünenthal GmbH (DE) 2015-10-07 EP disclosed
US-20150087648-A1 SUBSITUTED 2-(CHROMAN-6-YLOXYL)-THIAZOLES AND THEIR USE AS PHARMACEUTICALS SANOFI SA (FR) 2015-03-26 US disclosed
US-8912224-B2 Substituted 2-(chroman-6-yloxy)-thiazoles and their use as pharmaceuticals SANOFI (FR) 2014-12-16 US disclosed
US-20140243292-A1 SUBSITUTED 2-(CHROMAN-6-YLOXYL)-THIAZOLES AND THEIR USE AS PHARMACEUTICALS SANOFI (FR) 2014-08-28 US disclosed
WO-2014082739-A1 SUBSTITUTED AMINO-ARYLCARBOXAMIDES AS KCNQ2/3 MODULATORS Grünenthal GmbH (DE) 2014-06-05 WO disclosed
US-20140148454-A1 SUBSTITUTED AMINO-ACRYLCARBOXAMIDES AS KCNQ2/3 MODULATORS Grünenthal GmbH (DE) 2014-05-29 US disclosed
US-20130065859-A1 SUBSTITUTED 2-(CHROMAN-6-YLOXY)-THIAZOLES AND THEIR USE AS PHARMACEUTICALS SANOFI (FR) 2013-03-14 US disclosed
EP-0296673-B1 Thiazole derivatives SHELL INT RESEARCH (NL) 1994-03-09 EP disclosed
US-4877802-A FUNGICIDES SHELL INTERNATIONALE RESEARCH MAATSCHAPPIJ B.V. (NL) 1989-10-31 US disclosed
EP-0296673-A1 Thiazole derivatives SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) 1988-12-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180148440-A1 SUBSTITUTED 2-(CHROMAN-6-YLOXYL)-THIAZOLES AND THEIR USE AS PHARMACEUTICALS RYR2, SLC8B1, P2RX1 KMT2A 4098/4885POLB 4879/4885ACACB 2769/4885
US-20250084074-A1 SUBSTITUTED HETEROCYCLES AS HSET INHIBITORS VHL, CDKN1A, CCNI KMT2A 1128/4885POLB 1370/4885ACACB 1042/4885
US-20140243292-A1 SUBSITUTED 2-(CHROMAN-6-YLOXYL)-THIAZOLES AND THEIR USE AS PHARMACEUTICALS RYR2, CACNA1E, SLC8B1 KMT2A 4357/4885POLB 4869/4885ACACB 2355/4885
US-20130065859-A1 SUBSTITUTED 2-(CHROMAN-6-YLOXY)-THIAZOLES AND THEIR USE AS PHARMACEUTICALS RYR2, SLC8B1, RYR1 KMT2A 4266/4885POLB 4876/4885ACACB 2732/4885
US-20140148454-A1 SUBSTITUTED AMINO-ACRYLCARBOXAMIDES AS KCNQ2/3 MODULATORS KCNJ2, KCNQ1, KCNQ2 KMT2A 260/4885POLB 4716/4885ACACB 601/4885
US-20170037042-A1 SUBSTITUTED 2-(CHROMAN-6-YLOXYL)-THIAZOLES AND THEIR USE AS PHARMACEUTICALS RYR2, SLC8B1, P2RX1 KMT2A 4098/4885POLB 4879/4885ACACB 2769/4885
US-20150087648-A1 SUBSITUTED 2-(CHROMAN-6-YLOXYL)-THIAZOLES AND THEIR USE AS PHARMACEUTICALS RYR2, CACNA1E, SLC8B1 KMT2A 4357/4885POLB 4869/4885ACACB 2355/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.